| Market Capitalization (Millions $) |
19 |
| Shares
Outstanding (Millions) |
13 |
| Employees |
117 |
| Revenues (TTM) (Millions $) |
258 |
| Net Income (TTM) (Millions $) |
12 |
| Cash Flow (TTM) (Millions $) |
-21 |
| Capital Exp. (TTM) (Millions $) |
0 |
Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that is headquartered in Woodcliff Lake, New Jersey, United States. The company was founded in 2007, and it operates as a subsidiary of Eagle Parent Holdings LLC. It is involved in the development and commercialization of injectable drugs that address unmet medical needs.
Eagle Pharmaceuticals focuses on drugs that are difficult to administer or have a limited shelf life. The company's products are designed to improve the safety, efficacy, and convenience of existing therapies. The company has a dedicated research and development team that works on developing the most innovative drugs.
The company's portfolio of products includes injectable drugs for critical care, oncology, and orphan diseases. Among its most notable products are Ryanodex, a treatment for malignant hyperthermia, and Bendeka/Benqim, a treatment for chronic lymphocytic leukemia. Additionally, it offers injectable drugs for the treatment of pain, infections, and rheumatoid arthritis.
Eagle Pharmaceuticals' business model is based on licensing, developing, and partnering with other pharmaceutical companies to market and distribute its products. The company's primary target is the United States market, but it has operations in Europe, the Middle East, and Asia as well. Its products are marketed through a network of distributors and partners.
The company has partnerships with several pharmaceutical companies, including Teva, Lupin, and Dr. Reddy's Laboratories. Eagle Pharmaceuticals has also established partnerships with academic medical centers and research organizations to advance its drug development program.
In conclusion, Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of injectable drugs for difficult-to-treat medical conditions. Its innovative products are aimed at improving the safety, effectiveness, and convenience of existing therapies. The company is committed to building strong partnerships with other companies and research organizations to advance its drug development program.
Company Address: 50 Tice Boulevard Woodcliff Lake 7677 NJ
Company Phone Number: 326-5300 Stock Exchange / Ticker: NASDAQ EGRX
|
0.46% 